Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" (maintained) [1] Core Insights - The 2025 National Medical Insurance Negotiation results were announced, with 114 new drugs added to the medical insurance directory, achieving an overall success rate of 88%, the highest in nearly seven years, with a maximum price reduction of 94 [4][19] - The newly added drugs include monoclonal antibodies, bispecific antibodies, ADCs, siRNA, and small molecules, indicating a strong focus on innovative therapies [19][32] - The commercial insurance directory has added 19 innovative drugs, which, while not reimbursed by medical insurance, receive support for innovative drug applications, enhancing patient access and benefiting the innovative drug industry [5][24] Summary by Sections 1. National Medical Insurance Negotiation Results - The 2025 medical insurance directory added 114 new drugs, with a success rate of 88% and a maximum price reduction of 94% [4][13] - The total number of drugs in the national medical insurance directory reached 3,253, including 1,857 Western medicines and 1,396 traditional Chinese medicines [16][17] - The directory reflects a significant increase in the inclusion of innovative drugs, with 50 of the new additions classified as category 1 innovative drugs [19][21] 2. Commercial Insurance Directory - The commercial insurance directory added 19 innovative drugs, highlighting their clinical value and innovation [24][28] - The directory includes treatments for diseases such as Alzheimer's, rare diseases in children, and other critical conditions, showcasing a focus on addressing unmet medical needs [24][28] - The support for innovative drugs in the commercial insurance directory aims to fill gaps in patient coverage and enhance the overall healthcare system [25][28] 3. Market Performance - In the second week of December, the pharmaceutical and biotechnology sector declined by 1.04%, underperforming the CSI 300 index by 0.96 percentage points [6][34] - The medical research outsourcing sector showed the highest increase, up by 3.69%, while offline pharmacy and medical circulation sectors experienced the largest declines [6][36] 4. Recommended Companies - The report continues to favor innovative drugs and their supply chain, recommending companies such as Sanofi, Innovent Biologics, and others for investment [7][32]

Core Viewpoint - Junshi Biosciences aims to establish itself as a global innovative pharmaceutical company with a complete industry chain capability from drug discovery to commercialization, focusing on quality and innovation [2][3]. Company Overview - Junshi Biosciences, founded on December 27, 2012, and listed on July 15, 2020, specializes in the research and commercialization of monoclonal antibody drugs and other therapeutic proteins [7]. - The company's main revenue sources include drug sales (90.67%), technology licensing (8.74%), and other services (0.59%) [7]. Product Development - The company has developed a promising drug portfolio, including its core product, Toripalimab, which is the first domestically approved PD-1 monoclonal antibody in China, with 11 approved indications and one supplemental NDA under review [2]. - Toripalimab is also the first innovative biologic drug developed and produced in China to receive FDA approval, with approvals in multiple regions including the US, EU, and Australia [2]. - Junshi's self-developed Tifcemalimab is the first anti-tumor anti-BTLA monoclonal antibody to enter clinical development, currently undergoing two Phase III trials [2]. Vaccine Development - The company's subsidiary, JunTuo Biotech, is developing vaccine-related products, including monkeypox and Zika vaccines, which are currently in the preclinical development stage [3]. - A collaboration has been established with several research institutions and universities to jointly develop a recombinant protein vaccine for monkeypox [3]. Financial Performance - For the period from January to September 2025, Junshi Biosciences reported revenue of 1.806 billion yuan, a year-on-year increase of 42.06%, while the net profit attributable to the parent company was -596 million yuan, reflecting a year-on-year growth of 35.72% [8]. Market Position - As of September 30, 2025, Junshi Biosciences had 35,900 shareholders, with an average of 21,361 circulating shares per person, a decrease of 12.96% from the previous period [8]. - The company is positioned within the pharmaceutical and biotechnology industry, focusing on innovative drugs, precision medicine, and cancer treatment [8].

Core Insights - The release of the 2025 National Medical Insurance Drug List and the first version of the Commercial Health Insurance Innovative Drug List has significantly benefited innovative drug companies on the Sci-Tech Innovation Board [1] - A total of 9 innovative drugs from Sci-Tech Innovation Board companies have been included in the new list, showcasing their strong capabilities [1] - The simultaneous release of the commercial insurance drug list marks a substantial breakthrough in the multi-layered payment system of "medical insurance + commercial insurance" [1] Group 1: Inclusion in Medical Insurance - Nearly 90% of innovative drugs from Sci-Tech Innovation Board companies have received medical insurance support, accelerating their value release and development [2] - Junshi Bioscience's drug, Junsida, is the only domestic PCSK9-targeted drug for statin-intolerant patients included in the new medical insurance list [2] - Haichuang Pharmaceutical's drug, Hainaan, has been approved for treating metastatic castration-resistant prostate cancer and will enhance market promotion and patient accessibility [2] Group 2: New Drug Development - New anti-tumor drugs from companies like Ailis, Yifang Biotech, and Shenzhou Cell provide precise treatment options for major diseases such as lung cancer and head and neck squamous cell carcinoma [3] - Several drugs covering endocrine, hematology, tumor support, and autoimmune treatment areas have been quickly included in the medical insurance list, demonstrating efficient drug review and approval processes [3] Group 3: Commercial Health Insurance Directory - The first version of the Commercial Health Insurance Innovative Drug List enhances the national multi-layered medical security system, with a clear division of roles between basic medical insurance and commercial insurance [4] - Innovative drugs from leading companies like BeiGene have been among the first to be included in this new directory, showcasing their clinical value [4][5] Group 4: Renewal and Market Expansion - Successful renewal negotiations confirm the exceptional value and clinical status of innovative drugs from Sci-Tech Innovation Board companies [6] - Junshi Bioscience's drug, Tuoyi, has expanded its medical insurance coverage with new indications, benefiting a broader patient population [6] Group 5: R&D Investment and Innovation Cycle - R&D investment among Sci-Tech Innovation Board companies reached a new high in the first three quarters of 2025, with a year-on-year increase of over 10% and an R&D intensity of 42% [7] - The formation of a virtuous cycle of "R&D investment - innovation results - medical/commercial insurance support - market returns - reinvestment in R&D" is evident in the industry [7]

Group 1 - The core viewpoint of the news is that Junshi Biosciences has shown significant trading activity, with a notable financing balance and changes in stockholder composition [1][2] Group 2 - On December 10, Junshi Biosciences' stock increased by 0.58%, with a trading volume of 173 million yuan. The financing buy-in amount was 10.57 million yuan, while the financing repayment was 12.40 million yuan, resulting in a net financing outflow of 1.83 million yuan [1] - As of December 10, the total financing and securities lending balance for Junshi Biosciences was 1.375 billion yuan, with the financing balance at 1.361 billion yuan, accounting for 4.89% of the circulating market value, which is above the 70th percentile of the past year [1] - In terms of securities lending, on December 10, there were no shares repaid, with 2,807 shares sold short, amounting to 101,900 yuan at the closing price. The remaining short selling volume was 388,900 shares, with a short selling balance of 14.12 million yuan, exceeding the 90th percentile of the past year [1] Group 3 - Junshi Biosciences, established on December 27, 2012, and listed on July 15, 2020, focuses on the research and commercialization of monoclonal antibody drugs and other therapeutic protein drugs. The main revenue sources are drug sales (90.67%), technology licensing (8.74%), and technical services (0.59%) [2] - As of September 30, the number of shareholders for Junshi Biosciences was 35,900, an increase of 15.17% from the previous period, while the average circulating shares per person decreased by 12.96% to 21,361 shares [2] - For the period from January to September 2025, Junshi Biosciences reported a revenue of 1.806 billion yuan, a year-on-year increase of 42.06%, while the net profit attributable to shareholders was -596 million yuan, reflecting a year-on-year increase of 35.72% [2] - As of September 30, 2025, among the top ten circulating shareholders, E Fund's Science and Technology Innovation Board 50 ETF held 19.39 million shares, a decrease of 2.82 million shares from the previous period, while Huaxia's Science and Technology Innovation Board 50 ETF held 18.97 million shares, a decrease of 1.07 million shares [2]

Core Viewpoint - In 2025, the Chinese A-share market is showing a steady upward trend supported by favorable policies, with the China Securities Regulatory Commission urging listed companies to increase dividends, buybacks, and shareholdings to solidify their value foundation [1] Group 1: Executive Buybacks - Since 2025, 27 companies in the A-share market have seen significant executive buybacks, particularly in high-growth sectors like healthcare, new energy, and semiconductors [2] - For instance, Kelly Tai's executives increased their holdings by 2.3 million shares, a 14% increase, benefiting from the growing orthopedic medical demand due to an aging population [2] - DeYe shares' executives bought 120,000 shares, while Tuojing Technology's executives increased their holdings by 210,000 shares, a 12% rise, aligning with national policies on technological self-reliance [2] Group 2: Policy Support - Multiple significant policies in 2025 have led to a surge in positive announcements from listed companies, with 14 companies benefiting from adjustments in the national medical insurance catalog and the encouragement of private investment [3][5] - The national medical insurance catalog added 114 new drugs, including 50 innovative drugs, significantly enhancing the market accessibility and sales scale for companies like Junshi Biosciences and Hengrui Medicine [5] - The release of 13 opinions by the State Council encourages private capital participation in key sectors like railways and nuclear power, with companies like China Railway Construction benefiting from substantial project contracts [5] Group 3: Performance Support - Many of the 14 companies have solid operational performance, signing significant contracts or achieving key technological breakthroughs that underpin their investment value [6][7] - For example, JinkoSolar's TigerNeo 3.0 components achieved a production efficiency of 24.8% and secured global orders worth 15 GW, showcasing its competitive edge in the solar market [7] - Research and development investments in A-shares reached 745.69 billion yuan in the first half of 2025, with sectors like electronics and biomedicine leading the way, indicating a strong foundation for future growth [7] Group 4: Investment Opportunities - Investors should focus on companies with executive buybacks in high-growth sectors, those benefiting from policy adjustments, and firms with significant contracts or R&D breakthroughs [8][9][10] - The combination of internal confidence from executives and favorable industry trends creates a strong investment rationale [8] - Companies directly benefiting from long-term policy releases, such as those in the medical and infrastructure sectors, present stable investment opportunities [9]

Group 1 - The 2025 National Medical Insurance Drug List includes 114 new drugs, with 50 being innovative drugs, showing an overall success rate of 88%, an increase from 76% in 2024 [1] - Nine innovative drugs from the Sci-Tech Innovation Board have been included in the medical insurance list, highlighting the strength and vitality of these companies [1] - The first version of the Commercial Health Insurance Innovative Drug List has been released, complementing the basic medical insurance and providing new possibilities for patients to access cutting-edge treatments [4] Group 2 - Nearly 90% of new drugs approved by Sci-Tech Innovation Board companies have received medical insurance support, indicating a shift towards value realization for these companies [2] - The drug "Junshi Biological's Junshida" is the only domestic PCSK9-targeted drug for patients intolerant to statins, now included in the medical insurance list [2] - The successful renewal negotiations for several innovative drugs confirm their clinical value and market position, benefiting a wider patient population [6][7] Group 3 - Innovative drugs from companies like Baiji Shenzhou and Junshi Biological have been recognized for their clinical value and patient benefits, leading to their inclusion in the medical insurance list [7] - The R&D investment of Sci-Tech Innovation Board companies reached a new high in the first three quarters of 2025, with a year-on-year increase of over 10%, indicating a strong commitment to innovation [7] - The cycle of "R&D investment - innovation results - insurance support - market return - reinvestment in R&D" is being established and strengthened within the industry [7]

Core Viewpoint - Junshi Biosciences has received approval for clinical trials of JS207 (PD-1/VEGF dual antibody) and JS212 (EGFR/HER3 dual antibody ADC) and plans to initiate related clinical research soon [1] Group 1: Clinical Trials - The company is currently conducting Phase II clinical trials for JS207, exploring combinations with chemotherapy, monoclonal antibodies, and ADCs across multiple tumor types [1] - The company aims to explore various combination therapies to maximize the synergistic effects of its pipeline [1] Group 2: Development Challenges - The lengthy and complex process of drug development, from research to clinical trial approval and production, is subject to various uncertainties [1]

Core Insights - The new National Medical Insurance Directory and the first Commercial Health Insurance Innovative Drug Directory will be implemented nationwide starting January 1, 2026, showcasing the government's commitment to enhancing healthcare access [1] Group 1: National Medical Insurance Directory - Nine innovative drugs from the STAR Market have been included in the new National Medical Insurance Directory, highlighting the strength and vitality of innovative pharmaceutical companies [1] - The inclusion of products like Baiyue Shenzhou's Baihe An and Kaize Bai in the first Commercial Health Insurance Innovative Drug Directory provides broader payment pathways for cutting-edge treatments [1][4] Group 2: Innovative Drug Companies - Nearly 90% of STAR Market biopharmaceutical companies have received medical insurance support for their newly approved drugs, indicating a favorable environment for innovation [2] - Junshi Biosciences' drug, Junshida, is the only domestic PCSK9-targeted drug for statin-intolerant patients included in the new medical insurance directory [2] - Haichuang Pharmaceutical's first marketed drug, Hainan An, is set to launch in May 2025 for treating metastatic castration-resistant prostate cancer, with its inclusion in the 2025 medical insurance directory expected to enhance market promotion and patient accessibility [2] Group 3: Drug Development and Market Integration - New cancer drugs from companies like Shanghai Ailis and Yifang Biotech provide precise treatment options for major diseases, demonstrating the efficient integration of new drug reviews and medical insurance payments in China [3] - Successful renewal negotiations for innovative drugs from companies like Baiyue Shenzhou and Junshi Biosciences further expand medical insurance coverage, benefiting a wider patient population [5] Group 4: R&D Investment and Future Outlook - R&D investment among STAR Market innovative drug companies reached a new high in the first three quarters of 2025, with a year-on-year increase of over 10% and an R&D intensity of 42%, significantly surpassing the overall A-share level [6] - The continuous improvement and collaboration of support policies like medical insurance and commercial insurance are expected to foster the emergence of more world-class new drugs, contributing to the health of the Chinese population [6]

格隆汇12月10日丨君实生物(01877.HK)公告，截至本公告披露日，熊俊通过上海证券交易所系统以集中 竞价方式累计增持公司A股股份100,000股，约占公司总股本的0.01%，累计成交总额为人民币383.84万 元。本次增持计划尚未实施完毕，熊俊将继续按照相关增持计划，在增持计划实施期间内择机增持公司 股份。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* （於中華人民共和國註冊成立的股份有限公司） 承董事會命 上海君實生物醫藥科技股份有限公司 熊俊先生 主席 中國，上海，2025年12月10日 於本公告日期，本公司董事會包括執行董事熊俊先生、李寧博士、鄒建軍博士、 李聰先生、張卓兵先生、姚盛博士、王剛博士及李鑫博士；非執行董事湯毅先 生；以及獨立非執行董事張淳先生、馮曉源博士、酈仲賢先生、魯琨女士及楊勁 博士。 * 僅供識別之用 上海君實生物醫藥科技股份有限公司 （股份代號：1877） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條規則作出。 茲載列上海君實生物醫藥科技股份有限公司在上海證券交易所網站刊發之《上海 君實生物醫藥科技股份有限公司關於控股股東、實際控制人之一兼董事長增持股 份進展公告》，僅供參閱。 证券代码：688180 证券简称：君实 ...